| Literature DB >> 35498430 |
Meng-Jiao Gao1, Hui-Zhong Xue1, Rui Cai2, Bi-Yao Jiang1, Bao-Hong Mi3, Zong-Jun Chen1, Yin-Chun Shi1, Yong-Hua Xiao4, Wen-Zheng Zhang4.
Abstract
Objective: To explore the temperature distribution characteristics of the face, palms, feet and the trunk area of metabolic syndrome (MS) through infrared thermography (IRT) and provide evidence for the application of IRT in the assistant evaluation of MS population.Entities:
Keywords: abdominal obesity; evaluation method; hyperglycemia; hypertension; infrared thermography; metabolic syndrome; temperature
Mesh:
Year: 2022 PMID: 35498430 PMCID: PMC9042650 DOI: 10.3389/fendo.2022.851369
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1Delimitation of ROI.
Figure 2Study flow chart.
Baselines of age, measurement and laboratory data in groups (mean, minimum-maximum).
| Groups | M0 | M1 | M2 | M3 | χ2/F4 |
| F0 | F1 | F2 | F3 | χ2/F4 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | 26 | 18 | 16 | 31 | 50 | 21 | 10 | 12 | ||||
| Age (years) | 36.46 (23-58) | 36.60 (25-63) | 41.00 (24-61) | 43.16 (28-66) | 2.7881 | 0.045 | 33.50 (21-55) | 41.76 (27-60) | 44.10 (28-61) | 55.58 (38-69) | 16.0271 | 0.000 |
| Height (cm) | 172.55 (165.5-181.8) | 174.13 (167.0-185.4) | 173.24 (160.0-184.1) | 173.64 (155.0-187.0) | 0.3052 | 0.822 | 161.82 (150.5-177.8) | 161.88 (147.7-170.3) | 163.40 (155.8-171.0) | 160.07 (155.2-166.4) | 2.7083 | 0.439 |
| Body mass (kg) | 68.20 (60.6-79.75) | 71.18 (59.5-82.1) | 79.03 (64.0-99) | 88.31 (65.0-110.0) | 46.5863 | 0.000** | 54.74 (43.6-72.6) | 57.79 (43.8-74.6) | 66.84 (56.1-78.8) | 64.62 (52.0-82.2) | 19.5483 | 0.000** |
| BMI (kg/m2) | 22.85 (20.84-27.15) | 23.49 (21.04-25.89) | 26.28 (21.94-32.18) | 29.31 (23.34-38.51) | 51.8943 | 0.000** | 20.90 (16.52-26.63) | 22.03 (15.97-25.90) | 25.10 (20.52-31.39) | 25.30 (20.06-33.78) | 20.2433 | 0.000** |
| Waist circum-ference (cm) | 81.24 (72.0-87.0) | 86.22 (73.0-93.0) | 93.06 (78.0-111.0) | 100.20 (88.0-124.0) | 58.2193 | 0.000** | 72.11 (60.0-84.0) | 77.50 (68.0-91.0) | 82.40 (70.0-101.0) | 85.75 (72.0-99.0) | 30.9653 | 0.000** |
| Hip circum-ference (cm) | 94.87 (87.0-103.0) | 97.26 (92.0-103.0) | 101.68 (92.0-112.0) | 103.73 (93.3-116.0) | 37.0623 | 0.000** | 91.69 (81.0-104.0) | 94.13 (84.0-107.0) | 98.90 (91.0-110.0) | 95.00 (87.0-105.0) | 5.7002 | 0.001** |
| SBP (mmHg) | 115.89 (101-129) | 119.78 (107-137) | 123.88 (100-151) | 134.84 (99-172) | 19.9023 | 0.000** | 110.00 (97-127) | 119.05 (94-145) | 126.80 (102-151) | 124.08 (107-140) | 17.7293 | 0.001** |
| DBP (mmHg) | 68.85 (61-78) | 72.00 (60-87) | 77.56 (59-97) | 85.48 (53-112) | 27.8523 | 0.000** | 66.86 (53-85) | 73.19 (57-96) | 78.40 (65-94) | 77.25 (55-110) | 7.7432 | 0.000** |
| FPG (mmol/L) | 5.09 (4.38-5.74) | 5.57 (4.58-10.74) | 5.73 (4.37-8.54) | 7.27 (4.53-17.06) | 21.1563 | 0.000** | 4.96 (4.28-5.86) | 5.14 (4.34-7.11) | 5.56 (5.07-6.23) | 7.58 (4.94-11.19) | 30.4193 | 0.000** |
| UA (μmol/L) | 352.0 (328.1-375.9) | 364.7 (281.5-485.9) | 402.8 (309.5-488.6) | 414.7 (271.4-552.5) | 4.8312 | 0.004** | 253.9 (119.4-459.1) | 252.3 (137.7-414.5) | 289.8 (231.1-365.5) | 306.1 (206.7-434.33) | 10.6833 | 0.014* |
| TC (mmol/L) | 4.95 (3.71-6.39) | 4.98 (3.82-7.57) | 5.06 (3.56-7.00) | 5.08 (3.16-8.84) | 0.7193 | 0.869 | 4.87 (3.22-7.62) | 4.83 (3.52-6.01) | 5.44 (3.15-7.02) | 5.18 (4.20-7.25) | 6.4833 | 0.090 |
| TG (mmol/L) | 0.91 (0.32-1.69) | 1.25 (0.65-2.58) | 1.65 (0.73-4.17) | 2.88 (0.71-9.64) | 46.2533 | 0.000** | 0.78 (0.27-1.33) | 1.22 (0.46-2.59) | 1.40 (0.84-2.23) | 2.20 (0.80-4.83) | 33.7673 | 0.000** |
| HDL-C (mmol/L) | 1.41 (1.07-2.57) | 1.29 (0.88-3.14) | 1.18 (0.71-1.85) | 1.07 (0.63-2.18) | 23.9753 | 0.000** | 1.57 (1.16-2.54) | 1.45 (0.95-1.90) | 1.38 (0.79-2.40) | 1.17 (0.84-1.52) | 18.8063 | 0.000** |
| LDL-C (mmol/L) | 2.79 (1.84-4.07) | 2.91 (1.13-5.00) | 3.02 (1.47-4.24) | 2.82 (0.78-5.61) | 0.3722 | 0.773 | 2.60 (1.40-4.75) | 2.56 (1.81-3.87) | 3.12 (1.82-4.31) | 3.17 (0.79-4.84) | 8.0633 | 0.045* |
1ANOVA performed on the age of both gender groups (with variable transformation), Post-Hoc tests (Bonferroni method) showed no significance in ages between four male groups (P > 0.05), female group F1, F2 (P = 1.000), and F2, F3 (P = 0.106).
2For data that conformed to the normal distribution and homogeneity of variance, ANOVA was implemented.
3For data that did not conform to the homogeneity of variance, Kruskal-Wallis test was used.
4χ2/F refers to the χ2 value in Kruskal-Wallis test/F value in ANOVA.
*P < 0.05, ** P < 0.01.
Figure 3Comparison of Tmean of each ROI between different genders. *: P < 0.05 **: P < 0.01.
Comparison of Tmean of each ROI among four groups in each gender .
| Groups | M0 | M1 | M2 | M3 | χ2/F4 |
| F0 | F1 | F2 | F3 | χ2/F4 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | 26 | 18 | 16 | 31 | 50 | 21 | 10 | 12 | ||||
|
| 33.14 ± 0.72 | 33.41 ± 0.69 | 33.20 ± 0.46 | 33.40 ± 0.53 | 1.1572 | 0.331 | 32.76 ± 0.84 | 32.88 ± 0.71 | 32.73 ± 0.47 | 32.93 ± 0.36 | 1.8513 | 0.604 |
|
| 33.12 ± 0.50 | 32.76 ± 0.63 | 32.31 ± 0.50 | 32.00 ± 0.73 | 17.4052 | 0.000** | 33.14 ± 0.67 | 32.74 ± 0.69 | 32.56 ± 0.88 | 32.33 ± 0.79 | 13.4263 | 0.004** |
|
| 30.95 ± 2.16 | 31.48 ± 1.60 | 31.07 ± 1.78 | 32.06 ± 1.46 | 5.1553 | 0.161 | 29.88 ± 1.98 | 30.59 ± 1.93 | 30.64 ± 2.60 | 32.49 ± 1.56 | 14.6283 | 0.002** |
|
| 30.81 ± 2.18 | 31.34 ± 1.67 | 31.03 ± 1.64 | 31.87 ± 1.51 | 5.4303 | 0.143 | 29.61 ± 1.94 | 30.19 ± 2.04 | 30.37 ± 2.71 | 32.54 ± 1.53 | 17.6603 | 0.001** |
|
| 29.26 ± 1.95 | 29.41 ± 1.76 | 29.42 ± 1.49 | 29.74 ± 1.70 | 2.3303 | 0.507 | 28.43 ± 1.32 | 29.02 ± 0.87 | 28.95 ± 1.76 | 30.89 ± 1.14 | 23.7423 | 0.000** |
|
| 29.33 ± 2.07 | 29.41 ± 1.82 | 29.59 ± 1.51 | 29.77 ± 1.71 | 2.1283 | 0.546 | 28.39 ± 1.28 | 29.18 ± 0.95 | 28.84 ± 1.87 | 30.82 ± 1.10 | 23.3783 | 0.000** |
|
| 82.0621 | 60.0801 | 56.4961 | 97.6981 | 200.3261 | 67.4551 | 23.6181 | 29.3221 | ||||
|
| 0.000** | 0.000** | 0.000** | 0.000** | 0.000** | 0.000** | 0.000** | 0.000** |
1Kruskal-Wallis test was used for comparing Tmean of six ROI within each gender group.
2ANOVA followed by Bonferroni’s post-hoc test was implemented for comparing Tmean of each ROI between four male groups. In post-hoc test, significance was found between Tt of group M0/M2, M0/M3, M1/M3 (adjusted P<0.05).
3When comparing Tmean of each ROI between four groups in each gender, for data that did not conform to the normal distribution, Kruskal-Wallis test was used. Bonferroni correction showed significance between Tt and Trp of group F0/F3, Tlp of group F0/F3, F1/F3, Trf and Tlf of group F0/F3, F1/F3, F2/F3 (adjusted P < 0.05).
4χ2/F refers to the χ2 value in Kruskal-Wallis test/F value in ANOVA. ** P < 0.01.
Figure 4Tmean of each ROI of male groups - grouped by number of abnormal indexes. **: P < 0.01.
Figure 5Tmean of each ROI of male groups - grouped by ROI. **: P < 0.01.
Figure 6Tmean of each ROI of female groups - grouped by number of abnormal indexes. **: P < 0.01.
Figure 7Tmean of each ROI of female groups - grouped by ROI. **: P < 0.01.
Pearson correlation analysis between Tmean of each ROI and measurement data & laboratory data in female groups.
| Pearson Correlation Coefficient (r) | ||||||
|---|---|---|---|---|---|---|
| Tf | Tt | Trp | Tlp | Trf | Tlf | |
| Age (years) | -0.157 |
|
|
|
|
|
| Height (cm) |
|
| 0.014 | -0.007 | -0.013 | 0.018 |
| Body mass (kg) |
|
|
|
|
|
|
| BMI (kg/m2) | 0.127 |
|
|
|
|
|
| Waist circumference (cm) | 0.069 |
|
|
|
|
|
| Hip circumference (cm) | 0.185 |
|
|
| 0.190 | 0.196 |
| SBP (mmHg) | -0.001 | -0.177 | 0.023 | 0.025 | 0.116 | 0.112 |
| DBP (mmHg) | -0.071 |
| 0.043 | 0.049 | 0.081 | 0.071 |
| FPG (mmol/L) | 0.028 |
|
|
|
|
|
| UA (μmol/L) | 0.107 |
| 0.201 |
|
| 0.188 |
| TC (mmol/L) | -0.124 | -0.157 | 0.044 | 0.024 | 0.036 | 0.026 |
| TG (mmol/L) | 0.104 |
|
|
|
|
|
| HDL-C (mmol/L) | -0.161 |
|
|
|
|
|
| LDL-C (mmol/L) | -0.101 |
| 0.145 | 0.132 | 0.187 | 0.141 |
Bold r-values mean that the correlations between the corresponding Tmean and measurement data and laboratory data are statistically significant. *P < 0.05, ** P < 0.01.